Sign in

Gastric and oesophageal cancer: trials that stopped early

Trials on Gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.

  1. Terminated

    Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

    Reason given in the registry

    “Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment in another study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 May 2026.

    Ended
    Sept 2024
    Phase
    Phase 2
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT04034251
  2. Suspended

    Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)

    Reason given in the registry

    “Pending Protocol amendment”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 May 2026.

    Run by
    Rutgers, The State University of New Jersey
    Registry record
    NCT04929015
  3. Terminated

    A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

    Reason given in the registry

    “Patient recruitment problems.”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2026.

    Ended
    Dec 2025
    Phase
    Phase 1/2
    Run by
    Aurigene Discovery Technologies Limited
    Registry record
    NCT07040059
  4. Terminated

    A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

    Reason given in the registry

    “Patient recruitment problems”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2026.

    Ended
    Feb 2026
    Phase
    Phase 1
    Run by
    Aurigene Discovery Technologies Limited
    Registry record
    NCT05861947
  5. Terminated

    Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

    Reason given in the registry

    “PI leaving institution”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Apr 2026.

    Ended
    Jun 2025
    Run by
    The University of Texas Health Science Center at San Antonio
    Registry record
    NCT04600466
  6. Terminated

    A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer

    Reason given in the registry

    “Since activation, 3 subjects were enrolled but were ineligible for randomization to a treatment arm because of a positive diagnostic laparoscopy result. Given the repeat inability to enroll and randomize an eligible subject; accrual was halted.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2026.

    Ended
    Feb 2025
    Phase
    Phase 2
    Run by
    Baylor College of Medicine
    Registry record
    NCT05567835
  7. Suspended

    A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

    Reason given in the registry

    “Sponsor has decided to permanently close recruitment”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2026.

    Ended
    Oct 2026
    Phase
    Phase 1/2
    Run by
    Cancer Research UK
    Registry record
    NCT04908111
  8. Terminated

    Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

    Reason given in the registry

    “Business Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Apr 2026.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Conjupro Biotherapeutics, Inc.
    Registry record
    NCT04931823
  9. Suspended

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

    Reason given in the registry

    “Pending data analysis”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.

    Ended
    Jun 2026
    Phase
    Phase 4
    Run by
    University of Chicago
    Registry record
    NCT02366819
  10. Terminated

    Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

    Reason given in the registry

    “Due to lack of efficacy shown at the time of the interim analysis.”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Mar 2026.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    SOTIO Biotech AG
    Registry record
    NCT04234113
  11. Terminated

    A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group

    Reason given in the registry

    “Due to the extension of the clinical trial period due to a problem that occurred in the first patient of this study, there were concerns about business viability, so we decided to cancel this study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Mar 2026.

    Ended
    Dec 2023
    Phase
    Phase 3
    Run by
    CellSeed Inc.
    Registry record
    NCT04689594
  12. Withdrawn

    S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

    Reason given in the registry

    “Strategic development reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Feb 2026.

    Ended
    Jun 2026
    Phase
    Phase 1/2
    Run by
    Institut de Recherches Internationales Servier
    Registry record
    NCT05312372
  13. Terminated

    The PLATON Network

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Feb 2026.

    Ended
    Jun 2025
    Run by
    Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Registry record
    NCT05489250
  14. Terminated

    A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

    Reason given in the registry

    “Clinical Futility of TAK 500 met. No further development with this compound”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Jan 2026.

    Ended
    Jan 2025
    Phase
    Phase 1/2
    Run by
    Takeda
    Registry record
    NCT05070247
  15. Terminated

    A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

    Reason given in the registry

    “Business Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Jan 2026.

    Ended
    Nov 2025
    Phase
    Phase 1/2
    Run by
    Ocellaris Pharma, Inc.
    Registry record
    NCT04260802
  16. Withdrawn

    Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

    Reason given in the registry

    “The pharmaceutical company is not moving forward with this intervention due to lack of efficacy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Dec 2025.

    Phase
    Phase 2
    Run by
    Massachusetts General Hospital
    Registry record
    NCT07283848
  17. Terminated

    A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

    Reason given in the registry

    “The decision was not based on any safety concerns”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2025.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT05977322
  18. Terminated

    Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer

    Reason given in the registry

    “default inclusion”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Dec 2025.

    Ended
    Aug 2024
    Phase
    Phase 3
    Run by
    University Hospital, Lille
    Registry record
    NCT03042169
  19. Terminated

    A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

    Reason given in the registry

    “The trial was stopped early on the initiative of the sponsor on the basis of a change in the research and development strategy without safety concerns”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Dec 2025.

    Ended
    Jan 2024
    Phase
    Phase 1
    Run by
    Shanghai Junshi Bioscience Co., Ltd.
    Registry record
    NCT05427396
  20. Terminated

    Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

    Reason given in the registry

    “Business Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Nov 2025.

    Ended
    Jun 2025
    Phase
    Phase 1
    Run by
    Elevation Oncology
    Registry record
    NCT05980416
  21. Terminated

    Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

    Reason given in the registry

    “Recruitment challenges”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 2
    Run by
    Tempus AI
    Registry record
    NCT05169437
  22. Terminated

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

    Reason given in the registry

    “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Incyte Corporation
    Registry record
    NCT04272034
  23. Terminated

    A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

    Reason given in the registry

    “Sponsor's strategic business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2025.

    Ended
    Aug 2025
    Phase
    Phase 1
    Run by
    Actym Therapeutics, Inc.
    Registry record
    NCT06336148
  24. Terminated

    Futibatinib in Patients With Specific FGFR Aberrations

    Reason given in the registry

    “Sponsor made a strategic decision to terminate the study considering enrollment challenges for some of the cohorts in the trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2025.

    Ended
    Nov 2024
    Phase
    Phase 2
    Run by
    Taiho Oncology, Inc.
    Registry record
    NCT04189445
  25. Terminated

    A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

    Reason given in the registry

    “This study was terminated as a result of Sponsor portfolio reprioritization.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2025.

    Ended
    Apr 2025
    Phase
    Phase 1
    Run by
    NiKang Therapeutics, Inc.
    Registry record
    NCT06264921
  26. Terminated

    NIF-Guided RAMIE Using ICG Versus OTE Feasibility RCT

    Reason given in the registry

    “The study was closed due to adverse events because the adverse event rate was not lower than the adverse event rate in traditional open esophagectomy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Sept 2025.

    Ended
    Jun 2025
    Run by
    St. Joseph's Healthcare Hamilton
    Registry record
    NCT04938973
  27. Terminated

    A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Sept 2025.

    Ended
    Feb 2025
    Phase
    Phase 1/2
    Run by
    Bolt Biotherapeutics, Inc.
    Registry record
    NCT04278144
  28. Withdrawn

    Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

    Reason given in the registry

    “The primary reason for termination was difficulty in recruitment”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Aug 2025.

    Run by
    Hebei Medical University Fourth Hospital
    Registry record
    NCT06420908
  29. Terminated

    A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

    Reason given in the registry

    “Sponsor reprioritization of active trials.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Aug 2025.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    3B Pharmaceuticals GmbH
    Registry record
    NCT05605522
  30. Terminated

    Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer

    Reason given in the registry

    “Sponsor decision, the decision is not related to any safety concern.”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Aug 2025.

    Ended
    Nov 2024
    Phase
    Phase 2
    Run by
    Sanofi
    Registry record
    NCT05071053

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.